Minolexin in etiotropic therapy for 58 urogenital chlamydial infection

Abstract

Urogenital chlamydiasis is one of the most incident urogenital diseases transmitted sexually and through everyday contacts. Chronic chlamydial infection can lead to male and female infertility, intrauterine and postnatal infection, and promote the development of cardiovascular diseases and autoimmune processes. Chlamydial invasion in various tissues is responsible for a wide spectrum of clinical manifestations, presented by more than 20 syndromes and a spectrum of urogenital diseases: nongonococcal urethritis, vulvovaginitis, cervicitis, endometritis, salpingitis, epididymitis, prostatitis, proctitis, and extragenital chlamydiasis. Specific etiotropic therapy for chlamydiasis is carried out by antibacterial drugs penetrating into the cell. Among most effective antichlamydial drugs are tetracyclines, the drugs of choice, prescribed with combined therapy. Accumulated clinical experience experience accumulated by today demonstrates high activity of this antibiotic group in acute uncomplicated cervicitis and urethritis and in subacute chlamydial infections, in asymptomatic disease, in sexual partners without history ofprevious therapy, and in postgonorrheic chlamydiasis. Minolexin is a second-generation tetracycline. It is a highly effective antichlamydial drug, characterized by better pharmacokinetics than other tetracyclines, with high adsorption, long half-life period, lipolytic activity, no cross resistance, and with inhibitory effects on the matrix metalloproteinases. A clinical case with minolexin therapy is presented.

Keywords

chlamydial infection / urogenital chlamydiasis / etiotropic therapy / minolexin (minocycline)

References

[1] Молочков В.А. Урогенитальный хламидиоз. М.: БИНОМ; 2006: 9-119.

[2] Стрельников А.П., Гольцов С.В., Бушин Е.В., Ермакова А.В. Хламидийная инфекция урогенитального тракта. М.: Медицинская книга; 2005.

[3] Молочков В.А., Скирда Т.А., Алешкин В.А., Караулов А.В., Балюра Е.В., Молочкова Ю.В. К вопросу о лечении персистирующего урогенитального хламидиоза. Российский журнал кожных и венерических болезней. 2013; 4: 55-61.

[4] Исаков В.А., Архипова Е.И., Ермоленко Д.К. Терапия урогенитального хламидиоза: Руководство для врачей. СПб.: Тактик-Студио; 2002: 6-15.

[5] Кисина В.И., Забиров К.И. Урогенитальные инфекции у женщин. М.: Медицинское информационное агентство; 2005.

[6] Рищук С.В., Смирнова Т.С., Бойцов А.Г., Костючек Д.Ф., Дробченко С.Н. Диагностика и установление излеченности половых пар по урогенитальному хламидиозу и микоплазмозу. Методические рекомендации. СПб.: СпецЛит; 2006.

[7] Савичева А.М., Башмакова М.А. Урогенитальный хламидиоз у женщин и его последствия. Нижний Новгород: НГМА; 1998.

[8] Saivin S., Houin G. Clinical pharmacokinetics of doxycycline and minocycline Minocycline clinical pharmacokinetics. Clin. Pharmacokinet. 1988; 15(6): 355-66.

[9] Eady E.A., Cove J.H., Holland K.T., Cunliffe W.J. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated patients. Br. J. Dermatol. 1990; 122(2): 233-44.

[10] Oriel J.D., Ridgway G.L. Comparison of tetracycline and minocycline in the treatment of non-gonococcal urethritis. Br. J. Vener. Dis. 1983; 59(4): 245-8.

[11] Turnbull B.C., Stringer H.C., Meech R.J. Tetracycline and minocycline in the management of non-gonococcal urethritis: a comparison. N. Z. Med. J. 1982; 95(711): 460-2.

[12] Paulson D.F., Zinner N.R., Resnick M.I., Childs S.J., Love T., Madsen P.O. Treatment of bacterial prostatitis. Comparison of cephalexin and minocycline. Urology. 1986; 27(4): 379-87.

[13] Bowie W.R., Alexander E.R., Stimson J.B., Floyd J.F., Holmes K.K. Therapy for nongonococcal urethritis: doubleblind randomized comparison of two doses and two durations of minocycline. Ann. Intern. Med. 1981; 95(3): 306-11.

[14] Romanowski B., Talbot H., Stadnyk M., Kowalchuk P., Bowie W.R. Minocycline compared with doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Ann. Intern. Med. 1993; 119(1): 16-22.

RIGHTS & PERMISSIONS

Eco-Vector